

COHORT REVIEW

Peggy Wittie, PhD

TB and Hansen's Group Manager

October 28, 2014

COHORT REVIEW: OVERVIEW

❖ CRITICAL TOOL

- **CDC grant requirement for funding**
 - **Outcomes – linked to funding & part of suite of evaluation tools**
 - Desktop epidemiological review, audit, cohort review, annual progress report, etc
- TX Cohort Review Forms and process established by HSR, DSHS, and LHDs workgroup

❖ **COHORT REVIEW PROCESS** (def) – Systematic review of TB patient management and contacts

- **COHORT** (def) – Group of TB cases counted over a specific time period, and in Texas that is a year

Cohort Review: **History**

❖ Process developed in Africa

- Specifically to provide local clinics with necessary tools for complexity of TB control
 - To understand staff & resources needed to improve diagnosis of TB disease, initiate & complete tx, monitor adherence

❖ Huge Success! – led NYC Medical Director

- To implement in NYC program, and eventually went to all funded CDC TB Programs
- Saw improvement of completion rates
- Saw improved use of clinical resources & staff
- **NYC reported sharp decline in reported cases of MDR TB, from 441 cases in (1992) to 38 (in 1998) – huge success!**

COHORT PERIODS

- ❖ **By reviewing prior year's case cohort, the Epidemiology Evaluation Team can assess case management and patient outcomes**

Cohort Period & Submission Schedule

| Cohort Period Cases Counted In: | Are reviewed and reported by: |
|---|---|
| 1st quarter (Jan 1 to Mar 31) current year | March 31 of the following year |
| 2nd quarter (Apr 1 to June 30) current year | June 30 of the following year |
| 3rd quarter (July 1 to Sep 30) current year | September 30 of the following year |
| 4th quarter (Oct 1 to Dec 31) current year | December 31 of the following year |

COHORT REVIEW GOALS

- ❖ **Ensure accountability**
- ❖ Educate staff about protocols/goals
- ❖ **Improve case management & prevention efforts**
 - Staff will see day-to-day efforts reflected in cohort review process months later
 - Builds accountability for services provided
- ❖ **TB staff are responsible for:**
 - Ensuring *identification of high and medium priority contacts*
 - *Having patients/contacts who start tx to finish tx*

Clarifying **CASE REVIEWS** from cohort reviews

❖ **CASE REVIEWS –**

Regular review of individual patient's clinical course and tx by health care providers involved in process of **direct patient care**

- **Real-time, ongoing**
- **Opportunity to review each patient's specific care**
- Weekly, or once every two weeks basis
- Possible Participants: TB physician, clinic nurses, case registrar, contact investigator(s), outreach staff, and epidemiologist

❖ **PURPOSE**

- **Review one case at a time**
- **Discuss** clinical status, adherence, treatment status, CI status, timeliness, issues (i.e. a loose snake in house, etc)

COHORT REVIEW vs CASE REVIEW

- ❖ **Cohort Review** different – **more quantitative & retrospective, more epi based** – concern for outcomes
- ❖ Quantitative blend of program review & epidemiologic review of treatment (tx) outcomes
 - Reveals program strengths/ weaknesses
 - Shows needs for staff training/professional education
 - Increases tx completion, case mgmt processes & contact identification

COHORT REVIEW CHALLENGES

- ❖ Can be a challenge >> new process compared to case review
- ❖ Requires systematic commitment to:
 - Ongoing quality assurance process
 - Making necessary programmatic changes
 - Updating policies and procedures
 - Training & motivating staff
 - Following up and fixing problems identified

TB Jurisdictions – changes paradigms

Health Service Regions' Tuberculosis Cohort Review Infrastructure

Health Service Region 1

LHDs in Regional Cohort Case Count
Amarillo

Health Service Region 4/5N

LHDs in Regional Cohort Case Count
Cherokee
Smith

Health Service Region 2/3

LHDs in Regional Cohort Case Count
None

Report to Central Office

Tarrant
Dallas
Collin

Report to the Region

| | |
|---------|---------|
| Brown | Scurry |
| Grayson | Taylor |
| Hunt | Wichita |
| Navarro | Denton |
| Nolan | |

Health Service Region 6/5S

LHDs in Regional Cohort Case Count
Montgomery
Brazoria
Chambers
Hardin
Orange

Report to Central Office

Beaumont
Port Arthur
Galveston
Houston
Harris
Fort Bend

Health Service Region 7

LHDs in Regional Cohort Case Count
Waco/Mclennan
Milam
Brazos
Williamson
Hays

Report to Central Office

Austin-Travis

Health Service Region 8

LHDs in Regional Cohort Case Count
Uvalde
Victoria
Medina
Comal

Report to Central Office

San Antonio

Health Service Region 9/10

LHDs in Regional Cohort Case Count
Midland
Andrews
San Angelo

Report to the Region

Ector

Report to Central Office

El Paso

Health Service Region 11

LHDs in Regional Cohort Case Count
San Patricio
Live Oak

Report to Central Office

Cameron
Hidalgo
Nueces
Webb-Laredo

CDC Mandate for Enhanced Evaluative Processes

- ❖ Complies with CDC Mandates for enhanced review and evaluation of outcomes
 - Easy source of already prepared data with limited extra workload for jurisdictions
 - Will be linked to desktop review system to be instituted in year
 - Will be linked to additional training needs to ensure performance measures established by CDC are met

Cohort Review **Process**

❖ Scheduling

- TB Program Manager will coordinate and schedule case review dates with nurse case managers and staff
- A calendar of case reviews needs to be created
- All cases during the quarter are to be reviewed, not a subset

Cohort Review **Process**

❖ Preparation

- Pull medical records
- Prepare a calendar of case reviews
- Notify staff of dates & ensure that nurse case managers/nurses prepare their individual case reviews
- Reserve room quarterly for meeting with all clinical and programmatic staff
- Ensure that have satellite clinics nurses/staff participating to know what is and what is not working

Cohort Review: **Process** of reviewing cohort cases

- ❖ TB program mgr & medical reviewer
 - Listen to case presentations

 - Ask for details of staff efforts to solve problems
 - e.g., trace LTFU patients
 - provide feedback on issues

 - Suggest how to follow up on the patients & their contacts

- ❖ **More time on difficult cases**
 - Noncompliance, MDR/XDR TB, high # contacts, congregate settings

Cohort Review: **Process** of assessing programmatic needs

- ❖ **Data analyst updates registry information and notes items requiring follow up (F/U)**
 - At Cohort Review end, analyst evaluates objectives & prepares summary
 - Review of lapses in protocols, missing information, or incorrect info is noted and summarized
 - The Health Authority/Medical Director may use specific cases as examples of how to address certain ongoing or continuing problems
 - Needs for staff training & professional education are identified

Major Findings

- ❖ Data analyst should prepare major key findings that were revealed from all of the cases reviewed
 - Perhaps interviewing skills need to be enhanced if the community TB rate is higher than anticipated rate of TB in community
 - Call to TB Branch to discuss education options for staff
 - Documentation of lost to follow up processes since this is shown to be an issue needing to be addressed
 - Needs for staff training & professional education are identified
 - Complete evaluation and treatment completion rates are low

Issues that should be addressed

❖ **Issues to address**

- Not all clinical or satellite staff are involved in cohort review process
- Increasing number of cases from prior cases
- A cluster has occurred per the CDC definition for a genotyped cluster
- Issues that were identified in a state prior audit are still occurring
- Performance measures are consistently not met

Reporting & Documentation

- ❖ **Who needs to report:** all HSRs and funded LHDs TB clinics
 - DSHS HSRs TB programs will work with low morbidity LHDs in their jurisdiction to implement cohort review process

- ❖ **Documentation**
 - Case Registrar provides **list of cases** from cohort year

 - Nurses prepare **Presentation Forms**

 - **Summary Form** shall provide summarized and quantifiable data from all counted cases and associated contacts presented at each quarterly cohort review.

Old Data Reporting Elements

❖ Old Data Reporting Elements

- **Completed Cohort Review Summary Form**
 - Submit electronically to TB and Hansen's Group Manager by dates identified
 - Record every date held
 - Report total # of patients reviewed
 - Report # of cases, pulmonary or smear positive cases, # cases (and %) completing treatment, # contacts identified and with or without disease, evaluated, starting and completing treatment

New Data Reporting Elements

- ❖ For QA reasons, a list of **all cases** identified during cohort quarter year shall also be included
 - **Send through the PHIN for security purposes**
- ❖ For QA reasons, send **ALL** Presentation Forms developed by nursing staff for **EACH** case reviewed
 - **Send through the PHIN for security purposes**
 - **Provides key information for epidemiological evaluative analysis and QA review**

Cohort Instructions are online



Tuberculosis Services Branch Cohort Review Presentation Form (Instructions)

| | | |
|---|--|--|
| Quarter: <input type="checkbox"/> Q1 <input type="checkbox"/> Q2 <input type="checkbox"/> Q3 <input type="checkbox"/> Q4 Check the appropriate box for the quarter in which the case was counted | Cohort Year: Enter the year in which the case was counted | Presentation Date: Enter the date (month/day/year) the case was presented at the cohort review |
| Primary Case Manager: | Contact Investigator: | Treating Physician: |
| Section 1: Patient Information | | |
| Patient ID: This may be the RVCT number or a number selected by the local TB program | Date of Birth: Enter month/day/year | |
| Patient Name: | Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | |
| Date Case was Counted: Enter the month/day/year the suspect was classified as a case. | Country of Birth: The country in which the patient was born. | |
| Medical Risks (check all that apply): | | |
| <input type="checkbox"/> Diabetes Mellitus | <input type="checkbox"/> Recent Exposure to TB (contact to TB case) | <input type="checkbox"/> Cancer of Neck |
| <input type="checkbox"/> Alcohol Abuse (within past year) | <input type="checkbox"/> Contact to MDR-TB | <input type="checkbox"/> Drug Abuse within Past Year <input type="checkbox"/> TB Test Conversion in Last 2 Years |
| <input type="checkbox"/> Tobacco Use | <input type="checkbox"/> Weight at Least 10% Less Than Ideal Body Weight | <input type="checkbox"/> Fibrotic Lesions (on chest X-ray) Consistent with Old, Healed TB |
| <input type="checkbox"/> Silicosis | <input type="checkbox"/> Chronic Malabsorption Syndromes | <input type="checkbox"/> Chronic Renal Failure |
| <input type="checkbox"/> Corticosteroids or Other Immunosuppressive Therapy | <input type="checkbox"/> Leukemia | <input type="checkbox"/> Organ Transplant |
| <input type="checkbox"/> Gastrectomy or Jejunioileal Bypass | <input type="checkbox"/> Lymphoma | <input type="checkbox"/> Other: _____ |
| <input type="checkbox"/> Age < 5 Years | <input type="checkbox"/> Cancer of Head | |
| Code 900: Test Date: Enter month/day/year _____ <input type="checkbox"/> Not Offered <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Pending <input type="checkbox"/> Refused | Date CD4 Count: _____ Results CD4 Count: Enter CD 4 results here | |
| Section 2: Diagnostic Information | | |
| Disease Site: Indicate specific site(s) of disease | Initial Chest X-ray Date: _____ <input type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitary <input type="checkbox"/> Not Done | |
| Collection Date of Initial Positive AFB Smear: | Collection Date of Initial Positive MTB Culture: | |
| Resistance: <input type="checkbox"/> Yes <input type="checkbox"/> No susceptibility results indicate resistance | If Yes, Resistant to: List all anti-TB medications for which drug | |
| Section 3: Treatment Completion Information | | |
| Treatment Start Date: The date medication was started by month/day/year | Treatment Completion Date: The date medication was stopped due to patient successfully completing a full course treatment regimen by month/day/year | |
| Collection Date of First Consistently Negative AFB Smear: | Collection Date of First Consistently Negative MTB Culture: | |
| If treatment not completed, check all that apply: This refers to treatment not being completed at the time of the cohort presentation | | |
| <input type="checkbox"/> Still on Therapy (Planned Completion Date: _____) | | |
| <input type="checkbox"/> Treatment Interruption (<input type="checkbox"/> Adverse Reaction <input type="checkbox"/> Patient Non-adherence <input type="checkbox"/> Provider Decision) | | |

Cohort Instructions



Tuberculosis Services Branch Cohort Review Presentation Form (Instructions)

| | |
|--|--|
| <input type="checkbox"/> MDR | <input type="checkbox"/> Refused (Reason: _____) |
| <input type="checkbox"/> Lost | <input type="checkbox"/> Died (Date: _____) |
| <input type="checkbox"/> Reported at Death | <input type="checkbox"/> Moved out of Country (To: _____) |
| <input type="checkbox"/> Inter-jurisdictional Transfer (To: _____ Date: _____) | |
| <input type="checkbox"/> Other: If the above options do not accurately capture a reason for non-completion of treatment, describe in summary the reason treatment was not completed | |
| If Not on DOT Explain: Number of Recommended Doses: _____ Number of Doses Taken: _____ | |
| Section 4: Contact Investigation Results | |
| Genotype: <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, Cluster: Indicate PCR type (usually begins with the letter G) | |
| Number of Contacts Identified: Total number of contacts identified | Number of Contacts Evaluated: Total number of contacts that received appropriate screening (window/post window testing) including CXR, sputum collection for AFB testing if appropriate. |
| Number of Documented Prior Positives: Total number of contacts providing documentation reflecting previously positive TST or IGRA result | |
| Number of Contacts Infected <u>without</u> TB Disease: Total number of contacts that upon evaluation were asymptomatic, IGRA/TST-positive with a normal CXR | |
| Number of Contacts Identified as AFB Smear Positive: Total number of contacts that upon evaluation for possible TB disease including collection of sputum for acid fast bacilli testing was found to be smear positive | |
| Number of Contacts Identified with TB Disease: Total number of contacts that upon evaluation for TB disease including collection of sputum for acid fast bacilli testing was found to be positive for <i>Mycobacterium tuberculosis</i> | |
| Number of Contacts Eligible for Treatment of Latent TB Infection: Indicate the total number of contacts that upon evaluation was diagnosed with latent TB infection | |
| Number of Contacts that Started Treatment for LTBI: Total number of contacts that were started on treatment for LTBI Recent Documented Conversions: _____ the total number of contacts identified as converting from a negative TST/IGRA result to a positive TST/IGRA result within two (2) years of testing with IGRA/TST and started treatment for LTBI. Children ≤ 5 Years: _____ total number of children whose age at the time of the contact investigation was five (5) years of age or under, and upon evaluation were found to be infected with TB and started treatment for LTBI Known HIV+ Status: _____ total number of contacts with a documented HIV(+) status that were found to be infected with TB and started treatment for LTBI | |
| Number of Contacts Currently on Treatment for LTBI: Total number of contacts that at the time of the cohort presentation were still on treatment for latent TB infection | |
| Number of Contacts that Completed Treatment for LTBI: Total number of contacts that before or at the time of the cohort presentation successfully completed treatment for latent TB infection Recent Documented Conversions: _____ total number of contacts identified as converting from a negative TST/IGRA result to a positive TST/IGRA result within two (2) years and completed treatment for latent TB infection before or at the time of the cohort presentation Children ≤ 5 Years: _____ total number of contacts at or below the age of five (5) that completed treatment for latent TB infection before or at the time of the cohort presentation Known HIV+ Status: _____ total number of contacts with a documented HIV(+) status that completed treatment for latent TB infection before or at the time of the cohort presentation | |
| Number of Contacts that did not complete treatment for LTBI due to: Enter a number in the appropriate space to identify reasons contacts did not successfully complete treatment for latent TB infection _____ Still on Treatment _____ Adverse Reactions _____ Died _____ Moved _____ Refused _____ Lost | |

Questions

Thank you!